The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.

MLA

Murphy, Joseph, et al. “The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease.” American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, vol. 3, no. 2, 2003, pp. 101–12. EBSCOhost, https://doi.org/10.2165/00129784-200303020-00004.

APA

Murphy, J., Wright, R. S., Gussak, I., Williams, B., Daly, R. N., Cain, V. A., Pieniaszek, H. J., Sy, S. K. B., Ebling, W., Simonson, K., Wilcox, R. A., & Kopecky, S. L. (2003). The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, 3(2), 101–112. https://doi.org/10.2165/00129784-200303020-00004

Chicago

Murphy, Joseph, R Scott Wright, Ihor Gussak, Brent Williams, Robert N Daly, Valerie A Cain, Henry J Pieniaszek, et al. 2003. “The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease.” American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 3 (2): 101–12. doi:10.2165/00129784-200303020-00004.